Protagonist Therapeutics Inc (PTGX)

$81.36 +1.11 (1.38%)
Market Cap 5.02B
Revenue (ttm) 434.43M
Net Income (ttm) 275.19M
EPS (ttm) N/A
PE Ratio 129.39
Forward PE 271.93
Profit Margin 63.35%
Debt to Equity Ratio 0.00
Volume 799,000
Avg Vol 928,272
Day's Range N/A - N/A
Shares Out 62.52M
Stochastic %K 28%
Beta 2.26
Analysts Strong Sell
Price Target $95.92

Company Profile

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 474 0170
Address:
7707 Gateway Boulevard, Suite 140, Newark, United States
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 14 at 12:39 PM
$PTGX RSI: 23.76, MACD: -1.5961 Vol: 4.01, MA20: 86.09, MA50: 85.68 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
outlawinvestor1
outlawinvestor1 Jan. 13 at 4:23 PM
$PTGX icotrokinra is now ICOTIDE!
0 · Reply
Quantumup
Quantumup Jan. 13 at 12:01 PM
Guggenheim reiterated Best Idea $ABVX at Buy/$175 after hosting an investor dinner with Abivax's management yesterday. $LLY ABBV PFE $PTGX - JNJ Here's what Guggenheim said in its note: https://x.com/Quantumup1/status/2011044955871920247?s=20
0 · Reply
outlawinvestor1
outlawinvestor1 Jan. 13 at 4:27 AM
$PTGX JPM Healthcare Conference Day/Time: Tuesday, January 13 at 8:15 AM PST Webcast: https://jpmorgan.metameetings.net/events/healthcare26/sessions/317262-protagonist-therapeutics-inc/webcast?gpu_only=true&kiosk=true
0 · Reply
AlucardPendragon
AlucardPendragon Jan. 12 at 5:59 PM
$PTGX looks like i was wrong. Closed my position at a $1K loss
0 · Reply
AlucardPendragon
AlucardPendragon Jan. 9 at 8:29 PM
$PTGX I'm thinking they get bought out at$110 by JnJ on Monday
1 · Reply
Quantumup
Quantumup Jan. 8 at 11:45 AM
BTIG⬆️ $ABVX's PT to $150 from $120 and reiterated at a Buy after ABVX announced an updated 2026 outlook for their clinical pipeline. LLY PFE ABBV $PTGX - $JNJ Here's what BTIG had to say: https://x.com/Quantumup1/status/2009229128763953344?s=20
0 · Reply
Quantumup
Quantumup Jan. 8 at 11:09 AM
Leerink reiterated $ABVX Outperform/$138 LLY ABBV PFE $PTGX - $JNJ Citizens reiterated at a Market Outperform/$131 Here's what Leerink and Citizens had to say in their notes to investors: https://x.com/Quantumup1/status/2009220058770235789?s=20
0 · Reply
BluntForceOptions
BluntForceOptions Jan. 6 at 2:26 PM
$ALMS GM, y'all. This is why conviction matters in biotech. Congrats to everyone who stuck with this one and actually did the homework. Today’s massive move reflects the market finally responding to definitive Phase 3 validation after months of disconnect between fundamentals and price. I laid out the bull case well before this readout; this morning simply confirms it. Quick breakdown of today’s ONWARD Phase 3 data: Key Phase 3 takeaways (ONWARD1 & ONWARD2): Both trials met all primary and secondary endpoints with high statistical significance ~74% PASI-75 and ~59% sPGA 0/1 by Week 16 By Week 24, responses deepened meaningfully: ~65% PASI-90 40% PASI-100 Rapid onset, with separation from placebo on PASI-90 as early as Week 4 Outperformed apremilast across all PASI endpoints (p < 0.0001) Safety and tolerability were clean and consistent with Phase 2 -- no new signals Co plans to submit an NDA in 2H 2026 What matters here is where this lands competitively. External commentary today framed envudeucitinib as competitive with -- and in some measures rivaling -- other late-stage oral psoriasis programs from $JNJ / $PTGX and $TAK Takeda. That’s the real benchmark -- and ALMS just put itself squarely in that conversation. This is the payoff when a late-stage biotech delivers on Phase 3 execution: strong efficacy, durability, competitive differentiation, and a clean safety profile -- delivered at scale across two global Phase 3 trials. Giddy up.
1 · Reply
StockOrTwist
StockOrTwist Dec. 26 at 7:17 AM
$PTGX https://www.youtube.com/watch?v=MDMcQlTdDUQ
0 · Reply
Latest News on PTGX
Protagonist Therapeutics, Inc. (PTGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 5:35 PM EST - 14 hours ago

Protagonist Therapeutics, Inc. (PTGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026

Jan 7, 2026, 7:30 AM EST - 7 days ago

Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)

Jan 5, 2026, 7:00 AM EST - 9 days ago

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)

TAK

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

Dec 6, 2025, 9:30 AM EST - 5 weeks ago

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

TAK

Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 6, 2025, 4:05 PM EST - 2 months ago

Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting

Nov 3, 2025, 4:05 PM EST - 2 months ago

Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting

Johnson & Johnson To Acquire Protagonist? It'd Be A Good Deal To Make

Oct 12, 2025, 9:00 AM EDT - 3 months ago

Johnson & Johnson To Acquire Protagonist? It'd Be A Good Deal To Make

JNJ

RTW Investments' Rod Wong: Expect more deals in biotech space

Oct 10, 2025, 1:21 PM EDT - 3 months ago

RTW Investments' Rod Wong: Expect more deals in biotech space

JNJ XBI

Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report

Oct 10, 2025, 1:06 PM EDT - 3 months ago

Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report

JNJ

Johnson & Johnson in talks to acquire Protagonist Therapeutics, WSJ reports

Oct 10, 2025, 11:25 AM EDT - 3 months ago

Johnson & Johnson in talks to acquire Protagonist Therapeutics, WSJ reports

JNJ

Johnson & Johnson in Talks to Buy Protagonist Therapeutics

Oct 10, 2025, 11:13 AM EDT - 3 months ago

Johnson & Johnson in Talks to Buy Protagonist Therapeutics

JNJ

Protagonist Therapeutics, Inc. (PTGX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Sep 11, 2025, 1:08 AM EDT - 4 months ago

Protagonist Therapeutics, Inc. (PTGX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Protagonist Therapeutics, Inc. (PTGX) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 3, 2025, 1:39 PM EDT - 4 months ago

Protagonist Therapeutics, Inc. (PTGX) Presents At Citi's Biopharma Back To School Conference Transcript

Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025

Aug 26, 2025, 4:05 PM EDT - 5 months ago

Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025

Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 4:05 PM EDT - 5 months ago

Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate

Jun 26, 2025, 7:05 AM EDT - 7 months ago

Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate

Protagonist Therapeutics: Two 'Slam Dunk' Sets Of Pivotal Data Set Up Bull Case

Jun 20, 2025, 5:27 PM EDT - 7 months ago

Protagonist Therapeutics: Two 'Slam Dunk' Sets Of Pivotal Data Set Up Bull Case

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

Jun 1, 2025, 8:00 AM EDT - 8 months ago

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

TAK

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025

May 21, 2025, 7:05 AM EDT - 8 months ago

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025

Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025, 4:05 PM EDT - 9 months ago

Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update

Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025

Apr 23, 2025, 10:35 AM EDT - 9 months ago

Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025

Protagonist Therapeutics Reports Granting of Inducement Award

Apr 16, 2025, 4:05 PM EDT - 9 months ago

Protagonist Therapeutics Reports Granting of Inducement Award

Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025

Mar 18, 2025, 7:00 AM EDT - 10 months ago

Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025

Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It

Mar 11, 2025, 4:00 PM EDT - 11 months ago

Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It

Overlooked Stock: PTGX

Mar 10, 2025, 4:57 PM EDT - 11 months ago

Overlooked Stock: PTGX

Why Is Protagonist Therapeutics Stock Trading Higher On Monday?

Mar 10, 2025, 10:04 AM EDT - 11 months ago

Why Is Protagonist Therapeutics Stock Trading Higher On Monday?

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

Mar 3, 2025, 6:45 AM EST - 11 months ago

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

TAK

Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Feb 21, 2025, 7:00 AM EST - 11 months ago

Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck

Jan 13, 2025, 5:55 AM EST - 1 year ago

Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck

Protagonist Therapeutics Reports Granting of Inducement Awards

Jan 6, 2025, 4:05 PM EST - 1 year ago

Protagonist Therapeutics Reports Granting of Inducement Awards

Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025

Dec 19, 2024, 4:05 PM EST - 1 year ago

Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025

Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024

Nov 22, 2024, 7:30 AM EST - 1 year ago

Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024

Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate

Nov 19, 2024, 7:30 AM EST - 1 year ago

Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate

Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 7, 2024, 4:05 PM EST - 1 year ago

Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting

Nov 5, 2024, 4:05 PM EST - 1 year ago

Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting

Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines

Sep 10, 2024, 1:17 PM EDT - 1 year ago

Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines

Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 3, 2024, 7:30 AM EDT - 1 year ago

Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024

Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 6, 2024, 7:00 AM EDT - 1 year ago

Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor

Jul 31, 2024, 9:15 AM EDT - 1 year ago

Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor

Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024

Jul 22, 2024, 7:00 AM EDT - 1 year ago

Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024

May 31, 2024, 7:30 AM EDT - 1 year ago

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024

Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress

May 14, 2024, 4:05 PM EDT - 1 year ago

Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress

Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event

May 7, 2024, 4:10 PM EDT - 1 year ago

Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event

Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 7, 2024, 4:05 PM EDT - 1 year ago

Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update

Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data

Mar 26, 2024, 7:00 AM EDT - 1 year ago

Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data

Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda

Mar 18, 2024, 7:00 AM EDT - 1 year ago

Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda

Protagonist Therapeutics to Participate in Upcoming Investor Conferences

Mar 6, 2024, 4:05 PM EST - 2 years ago

Protagonist Therapeutics to Participate in Upcoming Investor Conferences

Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Feb 27, 2024, 4:05 PM EST - 2 years ago

Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera

Feb 21, 2024, 5:00 PM EST - 2 years ago

New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera

New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study

Feb 7, 2024, 5:00 PM EST - 2 years ago

New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study

OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 14 at 12:39 PM
$PTGX RSI: 23.76, MACD: -1.5961 Vol: 4.01, MA20: 86.09, MA50: 85.68 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
outlawinvestor1
outlawinvestor1 Jan. 13 at 4:23 PM
$PTGX icotrokinra is now ICOTIDE!
0 · Reply
Quantumup
Quantumup Jan. 13 at 12:01 PM
Guggenheim reiterated Best Idea $ABVX at Buy/$175 after hosting an investor dinner with Abivax's management yesterday. $LLY ABBV PFE $PTGX - JNJ Here's what Guggenheim said in its note: https://x.com/Quantumup1/status/2011044955871920247?s=20
0 · Reply
outlawinvestor1
outlawinvestor1 Jan. 13 at 4:27 AM
$PTGX JPM Healthcare Conference Day/Time: Tuesday, January 13 at 8:15 AM PST Webcast: https://jpmorgan.metameetings.net/events/healthcare26/sessions/317262-protagonist-therapeutics-inc/webcast?gpu_only=true&kiosk=true
0 · Reply
AlucardPendragon
AlucardPendragon Jan. 12 at 5:59 PM
$PTGX looks like i was wrong. Closed my position at a $1K loss
0 · Reply
AlucardPendragon
AlucardPendragon Jan. 9 at 8:29 PM
$PTGX I'm thinking they get bought out at$110 by JnJ on Monday
1 · Reply
Quantumup
Quantumup Jan. 8 at 11:45 AM
BTIG⬆️ $ABVX's PT to $150 from $120 and reiterated at a Buy after ABVX announced an updated 2026 outlook for their clinical pipeline. LLY PFE ABBV $PTGX - $JNJ Here's what BTIG had to say: https://x.com/Quantumup1/status/2009229128763953344?s=20
0 · Reply
Quantumup
Quantumup Jan. 8 at 11:09 AM
Leerink reiterated $ABVX Outperform/$138 LLY ABBV PFE $PTGX - $JNJ Citizens reiterated at a Market Outperform/$131 Here's what Leerink and Citizens had to say in their notes to investors: https://x.com/Quantumup1/status/2009220058770235789?s=20
0 · Reply
BluntForceOptions
BluntForceOptions Jan. 6 at 2:26 PM
$ALMS GM, y'all. This is why conviction matters in biotech. Congrats to everyone who stuck with this one and actually did the homework. Today’s massive move reflects the market finally responding to definitive Phase 3 validation after months of disconnect between fundamentals and price. I laid out the bull case well before this readout; this morning simply confirms it. Quick breakdown of today’s ONWARD Phase 3 data: Key Phase 3 takeaways (ONWARD1 & ONWARD2): Both trials met all primary and secondary endpoints with high statistical significance ~74% PASI-75 and ~59% sPGA 0/1 by Week 16 By Week 24, responses deepened meaningfully: ~65% PASI-90 40% PASI-100 Rapid onset, with separation from placebo on PASI-90 as early as Week 4 Outperformed apremilast across all PASI endpoints (p < 0.0001) Safety and tolerability were clean and consistent with Phase 2 -- no new signals Co plans to submit an NDA in 2H 2026 What matters here is where this lands competitively. External commentary today framed envudeucitinib as competitive with -- and in some measures rivaling -- other late-stage oral psoriasis programs from $JNJ / $PTGX and $TAK Takeda. That’s the real benchmark -- and ALMS just put itself squarely in that conversation. This is the payoff when a late-stage biotech delivers on Phase 3 execution: strong efficacy, durability, competitive differentiation, and a clean safety profile -- delivered at scale across two global Phase 3 trials. Giddy up.
1 · Reply
StockOrTwist
StockOrTwist Dec. 26 at 7:17 AM
$PTGX https://www.youtube.com/watch?v=MDMcQlTdDUQ
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Dec. 25 at 8:10 PM
$PTGX Trading at $88.84, with a high of $95.35 and a low of $35.09. Average volume stands at 995,142, recent volume around 154,100 to 2,227,500.
0 · Reply
StockOrTwist
StockOrTwist Dec. 25 at 7:41 PM
$PTGX https://youtu.be/MDMcQlTdDUQ
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Dec. 25 at 7:33 PM
Comparing trending tickers $CIGI vs $PTGX: CIGI has risen slightly by 0.60% to $149.91 with a trading volume of 29.4K, which is below its average of 129.2K. PTGX, on the other hand, has a smaller gain of 0.12%, reaching $88.84, but with a higher trading volume of 154.1K, significantly above its usual 995.1K. CIGI's price increase isn't matched by volume, while PTGX, despite its modest price change, is seeing much heavier trading activity.
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Dec. 25 at 6:34 PM
Comparing trending tickers $PTGX vs $CIGI: $PTGX Massive volume spikes recently compared to the average volume. Price has been moving between $85.79 and $88.84. Highest at $95.35 and lowest at $35.09. With such high volume, waiting for the H% to cool down before considering a position. Meanwhile, $CIGI Massive volume decrease today compared to the average volume of 129,157 shares. Price holding steady at $149.91 with recent volatility. Smart move might be to wait for a lower H% before considering an entry.
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Dec. 25 at 6:25 PM
my rules are simple for $PTGX - wait for H% to get low then buy
0 · Reply
biochirp
biochirp Dec. 22 at 4:25 PM
$ABVX J&J losing here means they’re forced to pickup $PTGX
0 · Reply
Quantumup
Quantumup Dec. 22 at 11:32 AM
a/o Friday: BMO Capital reiterated $IRON Outperform/$120 Jefferies reiterated Buy/$154 TD Cowen reiterated Buy Stifel analyst reiterated Buy/$125 $CLVLY Mitsubishi Tanabe Pharma $NVS ABBV GERN $PTGX - $TAK Here's what the Analysts had to say on Friday:
0 · Reply
Sw1ngb0t
Sw1ngb0t Dec. 19 at 10:21 PM
$HCTI $EOSE $PTGX $ONDS $NUVL
0 · Reply
justiceforb_85
justiceforb_85 Dec. 17 at 8:11 PM
$PTGX re-entered. Look forward to rusfertide approval, further development of icotrokinra, and advancement of PN-881 (oral IL-17 antagonist).
0 · Reply
JarvisFlow
JarvisFlow Dec. 17 at 5:54 PM
Barclays updates rating for Protagonist Therapeutics ( $PTGX ) to Overweight, target set at 88 → 108.
0 · Reply
Sw1ngb0t
Sw1ngb0t Dec. 13 at 9:22 PM
$PTGX $112.32+
0 · Reply
blueb22
blueb22 Dec. 12 at 7:57 PM
$PTGX - J&J BO should come out next week, otherwise it would be during JPM conference week. They have to buy it now. Other short term catalyst would be BLA filling for PV drug (reta) - PR could come today or by next Friday.
0 · Reply